Stock IMMX IMMIX BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Delayed Nasdaq
Other stock markets
 10:43:45 2024-05-16 EDT 		5-day change 1st Jan Change
2.39 USD +1.70% Intraday chart for Immix Biopharma, Inc. +9.63% -65.46%
05-10 Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral Presentation CI
05-09 Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immix Biopharma Announces Positive NXC-201 Relapsed, Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
AQ
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
AQ
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
GL
Immix Biopharma on Track to Dose NXC-201 Patients in United States
GL
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy
AQ
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
AQ
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
GL
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
AQ
Immix Biopharma Announces 'Be Proactive in AL' AL Amyloidosis Awareness Initiative
AQ
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
GL
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
AQ
Immix Biopharma 12 Month Review Progress Update
AQ
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
GL
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
AQ
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
GL
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
AQ
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
GL
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
AQ
Immix Biopharma Announces Proposed Public Offering of Common Stock
GL
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMMX Stock
  4. News Immix Biopharma, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW